Literature DB >> 2450256

Influence of endogenous bradykinin on acute blood pressure response to vasopressors in normotensive rats assessed with a bradykinin antagonist.

J F Aubert1, B Waeber, J Nussberger, R Vavrek, J M Stewart, H R Brunner.   

Abstract

The present study was designed to assess in conscious normotensive rats the influence of various pressor agents on the acute blood pressure response to a bradykinin antagonist (B4162). This antagonist was used at a dose (400 micrograms i.v.) which had been previously shown to block the blood pressure lowering effect of exogenous bradykinin for several minutes. In control rats, the bradykinin antagonist had no effect on blood pressure. However, in rats pretreated with nonpressor doses of angiotensin II or methoxamine or with pressor doses of vasopressin or methoxamine, the same antagonist significantly increased blood pressure by 10 +/- 2.2, 12 +/- 2.7, 9 +/- 1.7, and 16 +/- 3.4 mm Hg, respectively. It therefore appears that circulating bradykinin is not directly involved in blood pressure regulation of conscious normotensive rats. Endogenous bradykinin may however play an important role in blood pressure control by attenuating the pressor effect of angiotensin II, vasopressin, and alpha-adrenoceptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450256     DOI: 10.1097/00005344-198801000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells.

Authors:  P D'Orléans-Juste; G de Nucci; J R Vane
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

Review 2.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.

Authors:  B Waeber; L Juillerat-Jeanneret; J F Aubert; M Schapira; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.